华神科技：拟公开挂牌转让控股子公司西藏康域51%股权

Core Viewpoint - The company plans to transfer 51% equity of its subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd., through public listing, with a base price of RMB 63.7806 million, aiming to concentrate resources on core businesses and enhance profitability and competitive strength [1] Group 1 - The transaction is subject to approval by the company's shareholders' meeting, indicating uncertainty regarding its final realization [1]